AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05729074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A002 Ointment 0.5% or IN-A002 Placebo Ointment
Description: Drug: IN-A002 Ointment 0.5%, 10 g/1000 cm2, for 1 day Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2, for 1 day
Study NCT05729074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A002 Ointment 1% or IN-A002 Placebo Ointment
Description: Drug: IN-A002 Ointment 1%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
Study NCT05729074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A002 Ointment 3% or IN-A002 Placebo Ointment
Description: Drug: IN-A002 Ointment 3%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
Study NCT05729074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A002 Ointment 5% or IN-A002 Placebo Ointment
Description: Drug: IN-A002 Ointment 5%, 10 g/1000 cm2 Drug: IN-A002 Placebo Ointment, 10 g/1000 cm2
Study NCT05729074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A002 Ointment 1%
Description: Drug: IN-A002 Ointment 1%, 3 g/1000 cm2
Study NCT05729074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-A002 Ointment 3%
Description: Drug: IN-A002 Ointment 3%, 3 g/1000 cm2
Study NCT05729074 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elidel Cream 1% (pimecrolimus)
Description: Drug: Elidel Cream 1% (pimecrolimus), 3 g/1000 cm2
Study NCT05297045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RGT001-075
Description: Oral GLP1 Receptor Agonist
Study NCT05297045 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study NCT06260657 — intervention group
Intervention type: OTHER
Intervention: Histological analysis on fetal ethmoids
Description: Immunohistological analysis (immunohistochemical or immunofluorescent) on fetal ethmoids
Study NCT06126055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Band Ligation
Description: Placing bands in distal esophagus
Study NCT05145231 — intervention group
Intervention type: OTHER
Intervention: observational
Description: The scales will be filled by asking the family.
Study NCT06663306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Intrathecal pemetrexed 50mg,twice per week (d1, d8) for 1 week, then once per 4 weeks
Study NCT06663306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intrathecal bevacizumab, once (d8)for 1 week, then once per 4 weeks.The initial dose of intrathecal bevacizumab is 5 mg, escalated to 10 mg, and then 25 mg, and then 37.5mg, and then 50mg.
Study NCT05819749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Homelessness Medication Support Program in Spanish
Description: There will be 10 sessions offered within 12 weeks to participants. Sessions will last 30-60 minutes. During sessions a diabetes wellness coach will use behavioral activation and motivational interviewing to get to know participants and set goals to improve diabetes care. The coach will encourage a focus on medication adherence behaviors to the extent that participants are willing. The coach will also help with resources and care coordination. The coach will also provide brief diabetes education as needed.
Study NCT06460311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEDAL and EMS
Description: Group A will receive EMS with Stationary cycle. EMS will be given at quadricep muscles. The pads will placed vertically in the midline along the knee and the pelvis. EMS will be given at frequency = 35 to 70 Hz, pulse duration = 100 μs, pulse period = 50 ms, Intervention will be will be performed for 60 minutes for 3 times or week for 4 weeks.~Conversely, the endurance training phase will involve securing the cycle seat while children cycle at their maximum capacity, aiming for a heart rate between 70% to 80% of their maximum. Prior to and following each session, stretching exercises targeting the calf, quadricep, and hamstring muscles will be administered, with a 10-second hold during both the warm-up and cool-down sessions. Pre and post measurements will be conducted to evaluate mobility and gait
Study NCT06460311 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PEDAL
Description: In Group B, participants will exclusively receive the Pediatric Endurance and Limb Strengthening program without EMS. Similar to Group A, this program will incorporate the use of a stationary cycle. The warm-up and cool-down periods will also include a 10-second hold for each targeted muscle group. The intervention will consist of 60-minute sessions conducted three times per week over a span of four weeks.~Pre and post-assessments of gait and mobility will be conducted using the Gait Outcomes Assessment List (GOALTM) Questionnaire and the time up and go test.
Study NCT06539143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: The Paracervical Block with lidocaine for manual vacuum aspiration
Study NCT06539143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: The Paracervical Block with lidocaine for manual vacuum aspiration
Study NCT06111092 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Design Thinking
Description: Participants attend the DT session through all the stages that include emphasize, define, ideate, prototype and test.
Study NCT06111092 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Focus Groups
Description: Participants attend the FG that includes the introduction. discussion, and reflection.
Study NCT04803773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UFOGUIDE patient transducer
Description: The transducer is maintained by a flexible/rigid structure, consisting of a support base, and three to four feet forming an arch around the area to be treated. These feet exist in several lengths (10, 20, 30, 40 cm) depending on the area to be treated and can be easily mounted on the base by fast attachment. The structure is based on the principle of granular jamming: it is flexible in its normal state, and can be stiffened by the application of depression within the feet.
Study NCT06376773 — intervention group
Intervention type: PROCEDURE
Intervention: combination chemotherapy with Apatinib or Camrelizumab
Description: Apatinib, chemotherapy alone, Camrelizumab
Study NCT06542692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration
Description: treatment duration, frequency
Study NCT06542692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: physical therapy modalities
Description: ultrasound, hot pack, tens
Study NCT06140537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one tablet orally daily
Study NCT05667688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinlarebant (LBS-008)
Description: A single dose of Tinlarebant (LBS-008) will be administered to each study participant on study Day 1.
Study NCT06036173 — intervention group
Intervention type: OTHER
Intervention: diagnosis of lymphedema
Description: being diagnosed with secondary lymphedema in the upper extremity according to the International Lymphedema Association
Study NCT06036173 — intervention group
Intervention type: OTHER
Intervention: breast cancer surgery
Description: be diagnosed and undergo surgery
Study NCT06523309 — intervention group
Intervention type: OTHER
Intervention: Electroacupuncture treatment
Description: Electroacupuncture treatment consists of conventional acupuncture and electrical stimulation. After acupuncture, the electrical stimulation is continuously stimulated.
Study NCT06536218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CONSCIOUS AWARENESS STRESS REDUCTION PROGRAM APPLICATION
Description: CONSCIOUS AWARENESS STRESS REDUCTION PROGRAM APPLICATION Conscious Awareness Based Stress Reduction (BFTSA) intervention consists of seven sessions in total and is planned to be completed in a total of seven weeks, with one session per week and each session being 45 minutes. After the results of the PSG patients are determined according to the randomization criteria, they receive certain points from the sleep scale, it is planned to call the patients by phone and explain the meaning and importance of the study, the applications to be performed in the study and its duration. It is planned to hold online individual interviews with patients who agree to participate in this study.
Study NCT05264038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC514 (Low dose)
Description: Low dose level of OC514
Study NCT06025786 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Benazir Nashonuma Program (BNP)
Description: Benazir Nashonuma Program (BNP)~Dietary supplement for pregnant women and lactating mothers during the first six months of lactation:~Maamta is a 75-gram sachet made from peanut butter with 400 kcal of energy~Dietary supplement for children aged 6-23 months:~Wawamum is a lipid-based nutrient supplement consisting of skimmed milk powder, micronutrients, vegetable oil, roasted chickpeas and antioxidants. Wawamum covers the recommended daily dose of most micronutrients and 255 kcal of energy.~Conditional Cash Transfer (CCT):~This includes stipends of PKR 2000 during pregnancy contingent on three antenatal care visits, consuming SNF, attending awareness sessions on health and nutrition, getting two doses of tetanus toxoid and institutional delivery. After delivery PKR 2000/- for boys and 2500/- for girls are paid as incentives conditioned on getting child's birth registered, routine immunization and consumption of SNF by the child from 6-23 months
Study NCT05020730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTM-001
Description: PTM-001 (400 mg) every day for 12 weeks
Study NCT05020730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo every day for 12 weeks
Study NCT06611475 — intervention group
Intervention type: OTHER
Intervention: MMSE ≤26
Description: A dataset comprising participants with MMSE scores of ≤26 and 30 will be used to evaluate the classification performance of various machine learning techniques.
Study NCT05838222 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Solution Focused Intervention
Description: A short term, goal focused, therapeutic approach which helps patients address problems contributing to health and mental health challenges
Study NCT05838222 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: The patient receives standardized care from primary care team without the SFBT intervention
Study NCT05838222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: The patient receives standardized care from primary care team without the SFBT intervention
Study NCT04557722 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 0-30° Biplanar Fluoroscopic Puncture Techniques for Percutaneous Nephrolithotomy
Description: after retrograde instillation of contrast through the ureteric catheter; the puncture of the desired calyx by using the 0-30 degree technique of C-Arm.
Study NCT04557722 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: New 0-90° Fluoroscopic Puncture Techniques for Percutaneous Nephrolithotomy
Description: after retrograde instillation of contrast through the ureteric catheter; the puncture of the desired calyx by using the 0-90 degree technique of C-Arm.
Study NCT05595798 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Airmod breathing sound monitoring
Description: Respiratory monitoring and sedation depth monitoring will be applied during procedural sedation.
Study NCT06408454 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gingival crevicular fluid collection
Description: Samples were taken from two mandibular molar teeth. Before sampling, the sites were isolated with cotton rolls and then carefully dried with an air syringe to avoid saliva contamination. GCF was collected using sterile periodontal strips by gently inserting them into the gingival sulcus or pocket until slight resistance was noticed. After 30 s, the strips were collected into sterile tubes and immediately transported to the laboratory for storage (-40 °C) and posterior analysis.
Study NCT06408454 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: periodontal test
Description: A periodontist conducted the periodontal evaluation, which included a comprehensive assessment of clinical periodontal status, a full mouth manual periodontal charting, measurement of probing depth, clinical attachment level, bleeding on probing, and evaluation of mobility using a periotest device. Additionally, information regarding the patient's smoking status, frequency of smoking, and oral hygiene habits was obtained.
Study NCT04282733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Rounds
Description: Throughout the 8-week study period, a different mindfulness practice will be introduced weekly in 3 separate 15-minute live sessions. Posters describing the particular practice of the week will be placed around the Unit as visual reminders to encourage actual practice.
Study NCT04929522 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local anesthesia
Description: technique for local anesthesia
Study NCT06016413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: All patients received nab-paclitaxel 260 mg/m2 intravenously on day 1 of each 3-week cycle for 3 cycles.
Study NCT06016413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: All patients received carboplatin AUC=5 intravenously on day 1 of each 3-week cycle for 3 cycles.
Study NCT06016413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adelbelimumab
Description: All patients received carboplatin AUC=5 intravenously on day 1 of each 3-week cycle for 3 cycles.
Study NCT05414019 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mini-screw
Description: 7 patients will receive an intrusive force delivered by elastics from 2 mini-screws between mandibular lateral incisor and mandibular canine.
Study NCT05414019 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Utility arch
Description: 7 patients will receive an intrusive force delivered by intrusive utility arch.
Study NCT05414019 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nitinol reverse curve wire
Description: 7 patients will receive an intrusive force delivered by Nitinol reverse curve wire
Study NCT04832984 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile health
Description: Participants will be issued a fitness tracker, Bluetooth enabled glucometer, and a custom developed app which they can communicate digitally to the study investigators either as a group or individually. In the beginning of the study, participants will be taught on how to use the program, how to interact with their coach, and the importance of maintaining motivation throughout the program. Participants will have access to a pharmacist-participant messaging, group messaging, daily challenges for behavior change, education articles (biweekly bite-sized content over 24 weeks), food logging, steps and exercise logging, and feedback. They will be asked to log their weight, meals, and physical activity within the program on a weekly basis. Pharmacist will monitor participant progress through a web-based dashboard. Community pharmacist will be assisting users in setting specific, measurable, attainable, realistic, and time-based goals on a weekly basis.
Study NCT04832984 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will be issued a fitness tracker and Bluetooth enabled glucometer but these functions will not be enabled or linked to any app. All participants will be given physical tracking sheets to log in their food intake, blood glucose levels and food diary but will not have access to a personal coaching. Participants are free to seek any assistance for their medical care during the study period.
Study NCT06678191 — intervention group
Intervention type: DRUG
Intervention: BDP/FF/G (Beclomethasone diprprionate, formoterol fumarate, glycopyrronium bromide) 172/5/9 μg
Description: In accordance with the requirements of non-interventional studies, the assignment of patients to Trimbow 172/5/9 μg pMDI therapy should be made independently of the study, and patients should only be considered for inclusion in the study after a prior therapeutic decision has been made by a pulmonologist.
Study NCT06675695 — intervention group
Intervention type: DRUG
Intervention: New use of osimertinib
Description: New use of osimertinib described in electronic health records is used as the exposure.
Study NCT06675695 — intervention group
Intervention type: DRUG
Intervention: New use of erlotinib or gefitinib
Description: New use of standard of care described in electronic health records (erlotinib or gefitinib) dispensing claim is used as the reference.
Study NCT06319339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vumerity
Description: diroximal fumarate 462 mg (2 capsules)
Study NCT06319339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vumerity
Description: diroximal fumarate 462 mg (2 capsules)
Study NCT05264038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC514 (Mid dose)
Description: Mid dose level of OC514
Study NCT05264038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC514 (High dose)
Description: High dose level of OC514
Study NCT05264038 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match
Study NCT06319339 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Microcrystalline cellulose 462 mg (2 capsules)
Study NCT06319339 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Microcrystalline cellulose 462 mg (2 capsules)
Study NCT05443009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: A buccal infiltration injection followed by palatal injections and interpapillary injections of 2% lidocaine with 1:100,000 epinephrine will be administered.
Study NCT05443009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Articaine
Description: A single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered.
Study NCT06697483 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Daratumumab
Description: Patients who are R2-ISS 3 or 4 OR MRD (Minimal Residual Disease) positivity will receive daratumumab plus lenalidomide maintenance.
Study NCT06697483 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lenalidomide
Description: Patients are R2-ISS 1,2 and MRD (Minimal Residual Disease) negative after autologous stem cell transplantation.~Patients will receive the single drug lenalidomide maintenance.
Study NCT06701292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PVS-PVI targeted ablation
Description: Omnipolar technology will be used to analyze all PVs and delineate the PVMS. Once identified, PVMS will be marked and described in a clockface fashion using a lateral view of the vein.Ablation will target the PVMS using the same power and force parameters as described for the WACA procedure. Effective ablation lesions and distance between ablation spots will be represented in the same manner too. Lesions should cover at least 5 mm outside the PVMS delineation on both PVMS borders of each myocardial sleeve. PVI will be demonstrated with the same technique described in the WACA procedure.~The PVI will be verified for each vein 10 minutes after the initial achievement of PVI.
Study NCT06701292 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wide area circumferential ablation (WACA)
Description: After generating the 3D electroanatomical map of the heart to understand where treatment needs to be applied,using a tool called radiofrequency (RF) ablation, small burns will be made around the veins to block abnormal electrical signals. Each burn is applied with up to 50 watts of power and lasts up to 10 seconds.The ablation tool will press down with a force of around 10-20 grams.The mapping system (NAVX software) shows the burns on the 3D map
Study NCT06702345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: encapsulated 10^4 CFU toxigenic. C. difficile spores
Description: 12 consecutive days of once a day a capsule with 10\^4 CFU toxigenic C. difficile spores.
Study NCT06702345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: oral vancomycin pretreatment, 4 times a day 250mg, given the five days before toxigenic C. difficile exposure.
Study NCT06702345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: oral clindamycin pretreatment, 3 times a day 600mg, given the five days before toxigenic C. difficile exposure
Study NCT06702085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Management
Description: patients administered supervised changes in their lifestyle (walking exercise for 40 minutes applied on treadmill for three time per week and low caloric diet) for twelve weeks
Study NCT06700746 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prolotherapy
Description: Prolotherapy is an injection of a relatively small volume of an irritant or sclerosing solution at sites of painful ligament and/or tendon insertions, and in adjacent joint space over the course of several treatment sessions
Study NCT06700746 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shock wave therapy (ESWT)
Description: Extracorporeal shock wave therapy (ESWT), a kind of physical modalities, generating acoustic pulses, that are high positive pressure amplitudes, subsequently transferring concentrated energy to small focal distant areas of 2-8 mm in diameter
Study NCT06700655 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cornea limbal stem cell transplantation group
Description: The corneal limbal tissue (2mm x 5mm) was harvested from the patient's healthy eye, and ex vivo amplification was performed to obtain an adequate quantity of transplantable corneal limbal stem cells.